FibroGen to Attend May 2024 Investor Conferences

FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company based in San Francisco, has announced its participation in two upcoming investor conferences in May 2024. The company's management team will engage in the Bank of America Health Care Conference and the H.C. Wainwright 2nd Annual Bioconnect Investor Conference.

The Bank of America Health Care Conference will take place on Tuesday, May 14, 2024, in Las Vegas, NV. FibroGen will partake in one-on-one investor meetings, providing an opportunity for direct discussions with interested parties.

Following this, FibroGen will be present at the H.C. Wainwright 2nd Annual Bioconnect Investor Conference on Monday, May 20, 2024, in New York, NY. This event will feature a Fireside Chat scheduled from 5:00 to 5:30 PM ET, along with one-on-one investor meetings. Interested individuals can access a live audio webcast of the Fireside Chat through the "Events & Presentations" section of FibroGen’s Investor webpage, with a replay available for 30 days.

FibroGen, Inc. is dedicated to advancing novel therapies at the cutting edge of cancer biology. One of their lead products is Pamrevlumab, a fully human anti-CTGF monoclonal antibody. This drug is currently in clinical trials for treating metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer (LAPC).

Another significant product in FibroGen's portfolio is Roxadustat, marketed as 爱瑞卓® and EVRENZOTM. This medication is approved in several regions, including China, Europe, and Japan, for treating anemia in chronic kidney disease (CKD) patients, both on dialysis and not on dialysis. Roxadustat is also under clinical development for chemotherapy-induced anemia (CIA), and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority.

FG-3246, also known as FOR46, is a first-in-class antibody-drug conjugate (ADC) targeting CD46, under development for metastatic castration-resistant prostate cancer. This project includes work on a related CD46-targeted PET biomarker, enhancing the therapeutic approach.

Furthermore, FibroGen has broadened its research and development efforts to include two immuno-oncology product candidates aimed at treating solid tumors. This expansion underscores the company's commitment to exploring innovative solutions in cancer therapy.

FibroGen's participation in these investor conferences marks an opportunity to discuss its progress and future plans with investors and stakeholders, highlighting the ongoing advancements in their therapeutic pipeline.